中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

18 records (took 0.022 seconds)

    WOUND COATING MATERIAL
    3.
    发明专利
    WOUND COATING MATERIAL 失效

    公开(公告)号：JPH06142181A

    公开(公告)日：1994-05-24

    申请号：JP29434492

    申请日：1992-11-02

    Applicant: TORAY INDUSTRIES

    Inventor： SHOJI HISANORI ,  YAMAMOTO YASUHIRO ,  KODAMA MASATOMO ,  MITSUNAGA MASAHIRO ,  MURAKAMI MUTSUO ,  SUYAMA TOMOKO ,  NAGAYASU NAOTO

    IPC: A61K9/70 ,  A61K38/00 ,  A61L15/44 ,  A61K37/02

    Abstract: PURPOSE:To provide the wound coating material which exhibits an antimicrobial property even without releasing drugs and has a detoxication power to a bacterial toxin by immobilizing polypeptide antibiotics by cavalent bonding to the surfaces of fibers constituting cloth. CONSTITUTION:A polypeptide-based antibiotic is immobilized by covalent bonding to the surfaces of the fibers constituting cloth of a wound coating material. The ratio of the extension rate in the biaxial directions orthogonal to each other of the cloth surface is specified to >=50%. The cloth is formed of a knitted fabric cross knitted of blended fiber consisting of plural blank materials, combined filament yarns and/or plural fibers. As a result, the treatment of the wound is possible without allowing the intrusion of antibiotic into the body through the wound part, and therefore, side effects are prevented. Since an infection prevented, the treatment environment of the wound is improved and further the microbial cell toxin is adsorbed, and therefore an inflammation reaction is suppressed and healing is accelerated.

    ENDOTOXIN NEUTRALIZER
    5.
    发明专利
    ENDOTOXIN NEUTRALIZER 失效

    公开(公告)号：JPH05329207A

    公开(公告)日：1993-12-14

    申请号：JP262593

    申请日：1993-01-11

    Applicant: TORAY INDUSTRIES

    Inventor： KODAMA MASATOMO ,  TANI TORU ,  HANAZAWA KAZUYOSHI ,  OKAFUJI TARO ,  TERAMOTO KAZUO ,  SAIKAI SHIRO

    IPC: A61K47/00 ,  A61K9/70 ,  A61K47/30 ,  A61M1/14 ,  A61M1/36 ,  B01D15/08 ,  B01J20/28 ,  B01J20/32

    Abstract: PURPOSE:To weaken a side effect while taking advantage of the endotoxin neutralizing effect of polymixin by immobilizing the polymixin on a fibrous carrier having the substituent selected from an alpha-acyl halide group, benzyl halide group and isocyanic acid group, thereby preparing the endotoxin neutralizer. CONSTITUTION:The endotoxin neutralizer is prepd. by immobilizing the polymixin to the fibrous carrier having the substituent selected from the alpha-acyl halide group, the benzyl halide group and the isocyanic acid group. The fibrous carrier is selected from polystyrene fibers or crosslinked polystyrene fibers, acrylic acid acrylonitride copolymer fibers and polyvinyl alcohol fibers having a carboxyl group. Since the endotoxin neutralizer is formed by immobilizing the polymixin at a high density, the neutralizer is capable of decomposing and nontoxicating the endotoxin in a soln. Since the polymixin does not elute into the soln., the soln. treated with the neutralizer does not exhibit toxicity.

    ANTITUMOR SERUM OR PLASMA
    8.
    发明专利
    ANTITUMOR SERUM OR PLASMA 失效

    公开(公告)号：JPS6089425A

    公开(公告)日：1985-05-20

    申请号：JP19759083

    申请日：1983-10-24

    Applicant: TORAY INDUSTRIES

    Inventor： KODAMA MASATOMO ,  KATAYAMA YUTAKA ,  HORISAWA MASAHIRO ,  MIZUKURO TOMOYUKI ,  TANI TOORU ,  TERAMOTO KAZUO

    IPC: A61K35/74 ,  A61K35/14 ,  A61K35/16 ,  A61P35/00

    Abstract: PURPOSE:To obtain an antitumor serum or plasma exhibiting antitumor activity similar to a lipopolysaccharide at a low dose, and having high safety, by contacting fresh serum or plasma with an insoluble carrier bonded with a lipopolysaccharide originated from the cell wall of a Gram-negative bacteria, and concentrating the product. CONSTITUTION:Fresh serum or plasma is made to contact with an insoluble carrier bonded with a lipopolysaccharide originated from the cell wall of Gram- negative bacteria (abbreviated as lipopolysaccharide), preferably at 25-45 deg.C for 10-180min, and the product is concentrated to obtain the objective antitumor serum or plasma. The concentration is carried out under pressure or atmospheric pressure using a semipermeable membrane having a fractionation molecular weight of 54-20,000. The insoluble carrier bonded with the lipopolysaccharide is preferably the one containing a vinyl polymer as the stem polymer. The obtained agent has comparable antitumor effect to the lipopolysaccharide but does not exhibit lethal effect. Higher antitumor effect can be achieved at a low dose by the concentration procedure.

Patent Agency Ranking